Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE010 (ESP) (Dr. Silva)
· consented 2022-10-17
Adverse events
6
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-12-01 (study day 35); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-26 (study day 91); relationship: N
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-28 (study day 93); relationship: N
severe
assessed
2026-08-18
Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-02-16 (study day 112); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-15 (study day 200); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-08-09 (study day 286); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.